Issue #4: Revlimid
Added July 1, 2006 to the
Drug Monographs
Lenalidomide (Revlimid®)
Manufacturer: Celgene
Labeled FDA Approved Indications: Treatment of patients with transfusion-dependant anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Manufacturer: Celgene
Labeled FDA Approved Indications: Treatment of patients with transfusion-dependant anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.